NASDAQ:XTLB XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis $2.44 -0.02 (-0.81%) Closing price 03:59 PM EasternExtended Trading$2.44 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About XTL Biopharmaceuticals Stock (NASDAQ:XTLB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XTL Biopharmaceuticals alerts:Sign Up Key Stats Today's Range$2.39▼$2.4950-Day Range$2.30▼$3.9052-Week Range$2.12▼$10.28Volume9,357 shsAverage Volume151,935 shsMarket Capitalization$5.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel. Read More XTL Biopharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreXTLB MarketRank™: XTL Biopharmaceuticals scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingXTL Biopharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageXTL Biopharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about XTL Biopharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of XTL Biopharmaceuticals is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XTL Biopharmaceuticals is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXTL Biopharmaceuticals has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.23% of the float of XTL Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverXTL Biopharmaceuticals has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in XTL Biopharmaceuticals has recently decreased by 97.18%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXTL Biopharmaceuticals does not currently pay a dividend.Dividend GrowthXTL Biopharmaceuticals does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.92 News SentimentXTL Biopharmaceuticals has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for XTL Biopharmaceuticals this week, compared to 1 article on an average week.Search Interest1 people have searched for XTLB on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, XTL Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders29.00% of the stock of XTL Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions4.40% of the stock of XTL Biopharmaceuticals is held by institutions.Read more about XTL Biopharmaceuticals' insider trading history. Receive XTLB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XTLB Stock News HeadlinesXTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Staff Delist Determination from NasdaqMay 23, 2026 | finanznachrichten.deXTL Announces Receipt of Staff Delist Determination from NasdaqMay 22, 2026 | globenewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.May 29 at 1:00 AM | Banyan Hill Publishing (Ad)XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital RaiseMay 15, 2026 | tipranks.comXTL Biopharmaceuticals Ltd ADR XTLBMay 14, 2026 | morningstar.comMXTL Biopharmaceuticals Delays 20-F Amid Subsidiary LiquidationMay 3, 2026 | theglobeandmail.comXTL Biopharmaceuticals Ltd.May 1, 2026 | marketwatch.comWashington Just Opened the Door to Psychedelic Medicine; This Microcap Already Has a KeyMay 1, 2026 | theglobeandmail.comSee More Headlines XTLB Stock Analysis - Frequently Asked Questions How have XTLB shares performed this year? XTL Biopharmaceuticals' stock was trading at $2.3040 on January 1st, 2026. Since then, XTLB stock has increased by 5.9% and is now trading at $2.44. How were XTL Biopharmaceuticals' earnings last quarter? XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) announced its earnings results on Monday, December, 30th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter. When did XTL Biopharmaceuticals' stock split? Shares of XTL Biopharmaceuticals reverse split on Wednesday, March 25th 2026.The 1-4 reverse split was announced on Friday, March 20th 2026. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 24th 2026. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. How do I buy shares of XTL Biopharmaceuticals? Shares of XTLB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of XTL Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that XTL Biopharmaceuticals investors own include Regulus Therapeutics (RGLS), Akari Therapeutics (AKTX), Exelixis (EXEL), Gilead Sciences (GILD), Pfizer (PFE), Supernus Pharmaceuticals (SUPN) and Titan Pharmaceuticals (TTNP). Company Calendar Last Earnings12/30/2024Today5/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 XTLB's financial health is in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolNASDAQ:XTLB CIK1023549 Webwww.xtlbio.com Phone(729) 955-7080Fax972-3611-6605EmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$450 thousand Price / Sales11.93 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book0.99Miscellaneous Outstanding Shares2,200,000Free Float1,565,000Market Cap$5.37 million OptionableNot Optionable Beta1.64 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:XTLB) was last updated on 5/29/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
